The Renin-Angiotensin System in Essential Hypertension

This study is currently recruiting participants.

Verified by St George's, University of London, May 2007

Sponsored by:	St George's, University of London
Information provided by:	St George's, University of London
ClinicalTrials.gov Identifier:	NCT00141583

Purpose

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

Condition	Intervention
Hypertension	Drug: Enalapril 20 mg bd Drug: Candesartan 8 mg bd

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Candesartan cilexetil CV 11974 Enalapril Enalapril maleate Enalaprilat

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Randomized, Open Label, Active Control, Crossover Assignment
Official Title:	The Renin-Angiotensin System in Essential Hypertension

Further study details as provided by St George's, University of London:

Primary Outcome Measures:

Change in BP
Change in PRA and aldosterone

Estimated Enrollment:	11
Study Start Date:	April 2004
Estimated Study Completion Date:	October 2006

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Essential Hypertension
SBP 140-159 mmHg
DBP 90-99 mmHg

Exclusion Criteria:

Intolerance of or allergy to ACE Inhibitors or ARBS
Pregnant or Breastfeeding
Pre-menopausal women
Uncontrolled cardiac or renal failure
Diabetes mellitus

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00141583

Contacts

Contact: Timothy WR Doulton, BSc MRCP

+44 208 725 3176 ext -

tdoulton@sgul.ac.uk

Locations

United Kingdom
Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL	Recruiting
LONDON, United Kingdom, SW17 0RE
Contact: Timothy WR Doulton, BSc MRCP +44 208 725 3176 ext - tdoulton@sgul.ac.uk
Principal Investigator: Timothy WR Doulton, BSc MRCP

Sponsors and Collaborators

St George's, University of London

Investigators

Principal Investigator:

Timothy WR Doulton, BSc MRCP

SGUL

More Information

Study ID Numbers:	LREC 01.87.10
Study First Received:	August 31, 2005
Last Updated:	May 10, 2007
ClinicalTrials.gov Identifier:	NCT00141583
Health Authority:	United Kingdom: Research Ethics Committee

Keywords provided by St George's, University of London:

Renin-angiotensin system
ACE Inhibitor
Angiotensin Receptor Blocker

Study placed in the following topic categories:

Candesartan cilexetil
Enalapril
Enalaprilat
Candesartan

Vascular Diseases
Essential hypertension
Angiotensin II
Hypertension

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Cardiovascular Diseases

Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 13, 2009